Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
1.03.2008
The value of a QALY
Someone sent me this morning a refreshing editorial on the QALY/Threshold discussion. Its funny, well written and to the point. Definitely worth a read! Pharmacoeconomics 2008; 26 (1): 1-4
No comments:
Post a Comment